Mesenchymal stem cells produced from human pluripotent stem cells

Patent metadata

Field	Value
Publication number	US-9388384-B2
Application number	US-200913504881-A
Country	US
Kind code	B2
Filing date	Oct 28, 2009
Priority date	Oct 27, 2009
Publication date	Jul 12, 2016
Grant date	Jul 12, 2016

Abstract

Provided is a method for producing mesenchymal stem cells from human pluripotent stem cells, the method including: a) forming embryonic bodies from human pluripotent stem cells; b) attaching the embryonic bodies to a culture dish to induce natural differentiation of the embryonic bodies into mesenchymal stem cells; and c) performing continuous proliferative culturing of the mesenchymal stem cells while still maintaining the identity of the mesenchymal stem cells. Also, provided is a standardized method for inducing differentiation of mesenchymal stem cells, which can be broadly applied to all human pluripotent stem cells regardless of a difference in the genetic background thereof. Ultimately, the present invention can continuously mass-produces the mesenchymal stem cells necessary for regenerative medicine and cell therapy by using human pluripotent stem cells, thereby realizing practical uses of cell therapy products, and further the present invention is expected to highly contribute to treatments of incurable diseases, such as cardiovascular diseases and neurological disorders.

First claim

What is claimed is:

1. A method for producing mesenchymal stem cells from human pluripotent stem cells, the method comprising:
a) culturing the human pluripotent stem cells in an embryonic stem cell culture medium free from bFGF for 14 days to form embryonic bodies, wherein the embryonic body cells express one or more marker(s) selected from brachyury, BMPR, and Sox17;
b) attaching the embryonic bodies of step a) to a culture dish and culturing the embryonic bodies comprised of embryonic body cells in Dulbecco's Modified Eagle's Medium (DMEM) containing fetal bovine serum (FBS) to induce differentiation of the embryonic body cells into mesenchymal stem cells; and
c) maintaining and culturing the mesenchymal stem cells of step b) using a culture medium containing human epidermal growth factor (hEGF), vascular endothelial growth factor (VEGF), human fibroblast growth factor-basic (hFGF-B), insulin-like growth factor (IGF-1), hydrocortisone, and ascorbic acid,
wherein the mesenchymal stern cells of steps b) and c) express one or more markers selected from the group consisting of CD29, CD44, CD73, CD90 and CD105, and
wherein the mesenchymal stem cells of step c) are capable of being differentiated into cells selected from the group consisting of adipocytes, osteocytes, chondrocytes, myocytes, neurocytes, and cardiomyocytes.

2. The method of claim 1 , wherein the mesenchymal stem cells phenotype comprises CD29(+), CD44(+), CD73(+), CD90(+), CD105(+), SSEA-1(−), SSEA-4(−), TRA-1-60(−), CD45(−), and CD34(−).

Assignees

• Kim Hyo Soo
• Kang Hyun Jae
• Lee Eun Ju
• Park Young Bae
• Snu R&Db Foundation

Inventors

• Kim Hyo Soo
• Kang Hyun Jae
• Lee Eun Ju
• Park Young Bae

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C12N2506/02

  from embryonic cells · CPC title

• C12N2500/38

  Vitamins · CPC title

• C12N2501/11

  Epidermal growth factor [EGF] · CPC title